Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
about
Adjuvant therapy for resected pancreatic cancerPerioperative nutrition in patients undergoing resection for pancreatic malignancyPerioperative nutrition in patients undergoing resection for pancreatic malignancyPhase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cellsInvasion and metastasis in pancreatic cancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Systemic therapy of non-colorectal gastrointestinal malignancies in the elderlyProton therapy for pancreatic cancerPerioperative Therapy for Surgically Resectable Pancreatic AdenocarcinomaMicrobubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer.Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data BaseCorticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer.Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the InterdisciplinaAdjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trialsEvolution of systemic therapy for advanced pancreatic cancer.Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study.Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinomaAdjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative studySequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191Chemotherapy and tumor microenvironment of pancreatic cancer.Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma.A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4.A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.The role of radiotherapy in multimodal treatment of pancreatic carcinomaPancreatic cancer-improved care achievableTrends in the treatment of resectable pancreatic adenocarcinoma.Retinoid signaling in pancreatic cancer, injury and regeneration.Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data.Validation of group B borderline resectable pancreatic cancer: retrospective analysis.Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality.Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.Adjuvant therapy in pancreatic cancer.RON is not a prognostic marker for resectable pancreatic cancer.Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704
P2860
Q24186323-CFFC0513-7EC6-4C8B-BFD0-B216E7067E3BQ24235991-8ADF9A4D-28A4-4007-B29D-711A121202B6Q24240393-424C0519-2A81-4186-92AD-CFDB8B1093E8Q24792780-2E54BB27-A7D6-496A-B55B-D0650E1EF3C5Q24796817-82098525-7BBA-4328-86D2-46371B1E4A97Q24800065-44864590-DE6B-49C9-A1C7-75197167C97AQ26746031-5D05BC15-6C38-4218-B46A-7F7038C0AE62Q26771399-E7CCD2E3-15FE-40FB-81D6-82E2DE632D74Q26784227-36CEE61B-0C6C-44E0-8E79-BE6A1BE36A32Q26801411-846D4477-043C-4664-8D48-9DA8FE7CF7D3Q30464745-6A4A556C-6FFC-41BB-8A93-D331D8212050Q30726275-F0470891-ACD2-40E3-A24E-06FF2ACF03C7Q33235435-104954BD-01BF-4448-B895-C72C4025B7C5Q33276956-AA48902A-68AC-4AD2-B479-9594814CF260Q33398018-F0DAFD8B-789E-48C8-B321-B9A59D6AFF3DQ33557413-9E84C684-9792-4994-AB1E-25C66BD59202Q33559203-E6889A4E-C10A-4452-8C36-1EDD41DA5D83Q33631833-2008301A-A250-40F5-9439-9A940248A35DQ33733149-2AB90825-DB87-4B4F-882F-7FD898A27F73Q33735469-E4E67388-A694-493E-AA19-E72E4B3EC5EAQ33755147-5E22D908-E7FB-4D94-BE5F-F985C9F648D4Q33876637-9EB83031-610E-4528-A73E-439B38FB3D2FQ33920568-76D65666-1AB1-4A13-BDD2-453FD440709AQ33928176-7DA2E620-88FD-42D5-9DFC-6BD2BF1A5BE1Q33951007-DCFFD923-1349-49CB-99F9-4987D25DE33FQ33989971-77F3F2F0-F9FC-4950-94AB-AEDB8600CE5AQ33992146-18D810CC-01D9-4379-984C-332E0DADF57DQ34025910-415EAAD3-EE6B-4586-9303-1A77D563C696Q34036659-A7EE9722-4FA1-4B38-AE52-D23D63F5C78FQ34062486-6433C354-9F81-4201-B41B-DA4695B96C33Q34119073-6C39065F-B3FB-4810-B556-0ECFD5E4ECCDQ34152694-748BA778-1FC1-4E37-9751-E83C466BF4F9Q34182126-231BCCC9-74DE-4641-9B79-2C59EBCD6447Q34224734-81465EAB-BFC2-418D-AE3F-BB248EDFFE26Q34246396-6D2D2D16-BBB3-4785-AE5C-4FC5A56117EEQ34331762-DA3E4A78-5363-4958-9FAD-9BB01B3BCF02Q34405072-2D32F405-F4CD-4D29-8258-508134862120Q34408923-8AB570C0-0D5D-43ED-9027-81B3D4EB99B2Q34414547-0C2A8995-3ED0-4188-9032-D153E1F1CA6BQ34600819-EFC996FC-5A83-4DC6-9CF6-36FAE6DA8D7B
P2860
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@en
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@nl
type
label
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@en
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@nl
prefLabel
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@en
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@nl
P2093
P1433
P1476
Adjuvant chemoradiotherapy and ...... a randomised controlled trial.
@en
P2093
C Dervenis
D D Stocken
European Study Group for Pancreatic Cancer
P304
P356
10.1016/S0140-6736(01)06651-X
P407
P577
2001-11-01T00:00:00Z